AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

In response to the overwhelming generosity shown, the Immune Deficiency Foundation's president & CEO, Jorey Berry, thanked Ironmouse for her efforts. The organization released a video on its official ...

Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ...

AstraZeneca announced on Thursday that its investigational treatment ‘gefurulimab’ achieved statistically significant and ...

Findings published in JAMA Dermatology suggest that the use of immune checkpoint inhibitors may double psoriasis risk for ...

Meet 12 biotech companies with promising genetic disease therapies that successfully closed funding rounds recently.

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of targeted drugs are currently available, including lebrikizumab, dupilumab, and ...

A young Lithuanian woman was struggling to conceive, and according to a new report, a shocking allergy was the culprit.

Researchers at Uppsala University have identified a promising therapeutic approach for the challenging blood cancer multiple ...

One dose of the HPV vaccine in girls aged 9–14 triggers strong, lasting immune responses, comparable to a full three-dose ...

Gefurulimab is a dual-binding nanobody designed to bind to the C5 protein in the terminal complement cascade and prevent the overactivation of the body’s immune system.